1
|
Hatano R, Itoh T, Otsuka H, Saeki H, Yamamoto A, Song D, Shirakawa Y, Iyama S, Sato T, Iwao N, Harada N, Aune TM, Dang NH, Kaneko Y, Yamada T, Morimoto C, Ohnuma K. Humanized anti-IL-26 monoclonal antibody as a novel targeted therapy for chronic graft-versus-host disease. Am J Transplant 2022; 22:2804-2820. [PMID: 35997569 DOI: 10.1111/ajt.17178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2022] [Revised: 07/12/2022] [Accepted: 08/17/2022] [Indexed: 01/25/2023]
Abstract
IL-26 is a Th17 cytokine, with its gene being absent in rodents. To characterize the in vivo immunological effects of IL-26 in chronic systemic inflammation, we used human IL26 transgenic (hIL-26Tg) mice and human umbilical cord blood mononuclear cells (hCBMC) in mouse allogeneic-graft-versus-host disease (GVHD) and chronic xenogeneic-GVHD model, respectively. Transfer of bone marrow and spleen T cells from hIL-26Tg mice into B10.BR mice resulted in GVHD progression, with clinical signs of tissue damage in multiple organs. IL-26 markedly increased neutrophil levels both in the GVHD-target tissues and peripheral blood. Expression levels of Th17 cytokines in hIL-26Tg mice-derived donor CD4 T cells were significantly increased, whereas IL-26 did not affect cytotoxic function of donor CD8 T cells. In addition, granulocyte-colony stimulating factor, IL-1β, and IL-6 levels were particularly enhanced in hIL-26Tg mice. We also developed a humanized neutralizing anti-IL-26 monoclonal antibody (mAb) for therapeutic use, and its administration after onset of chronic xenogeneic-GVHD mitigated weight loss and prolonged survival, with preservation of graft-versus-leukemia effect. Taken together, our data elucidate the in vivo immunological effects of IL-26 in chronic GVHD models and suggest that a humanized anti-IL-26 mAb may be a potential therapeutic agent for the treatment of chronic GVHD.
Collapse
Affiliation(s)
- Ryo Hatano
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Takumi Itoh
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan.,Atopy (Allergy) Research Center, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Haruna Otsuka
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Harumi Saeki
- Department of Human Pathology, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Ayako Yamamoto
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Dan Song
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Yuki Shirakawa
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Satoshi Iyama
- Department of Hematology, Sapporo Medical University School of Medicine, Hokkaido, Japan
| | - Tsutomu Sato
- Department of Hematology, Toyama University Hospital, Toyama, Japan
| | - Noriaki Iwao
- Department of Hematology, Juntendo University Shizuoka Hospital, Shizuoka, Japan
| | - Norihiro Harada
- Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan
| | - Thomas M Aune
- Department of Medicine, Vanderbilt University School of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Nam H Dang
- Division of Hematology/Oncology, University of Florida, Gainesville, Florida, USA
| | | | - Taketo Yamada
- Department of Pathology, Saitama Medical University, Saitama, Japan.,Department of Pathology, Keio University School of Medicine, Tokyo, Japan
| | - Chikao Morimoto
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Kei Ohnuma
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| |
Collapse
|
2
|
Komiya E, Tominaga M, Hatano R, Kamikubo Y, Toyama S, Sakairi H, Honda K, Itoh T, Kamata Y, Tsurumachi M, Kishi R, Ohnuma K, Sakurai T, Morimoto C, Takamori K. Peripheral endomorphins drive mechanical alloknesis under the enzymatic control of CD26/DPPIV. J Allergy Clin Immunol 2021; 149:1085-1096. [PMID: 34411589 DOI: 10.1016/j.jaci.2021.08.003] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2020] [Revised: 06/29/2021] [Accepted: 08/02/2021] [Indexed: 11/18/2022]
Abstract
BACKGROUND Mechanical alloknesis (or innocuous mechanical stimuli-evoked itch) often occurs in dry skin-based disorders such as atopic dermatitis and psoriasis. However, the molecular and cellular mechanisms underlying mechanical alloknesis remain unclear. We recently reported the involvement of CD26 in the regulation of psoriatic itch. This molecule exhibits dipeptidyl peptidase IV (DPPIV) enzyme activity and exerts its biologic effects by processing various substances, including neuropeptides. OBJECTIVE The aim of the present study was to investigate the peripheral mechanisms of mechanical alloknesis by using CD26/DPPIV knockout (CD26KO) mice. METHODS We applied innocuous mechanical stimuli to CD26KO or wild-type mice. The total number of scratching responses was counted as the alloknesis score. Immunohistochemical and behavioral pharmacologic analyses were then performed to examine the physiologic activities of CD26/DPPIV or endomorphins (EMs), endogenous agonists of μ-opioid receptors. RESULTS Mechanical alloknesis was more frequent in CD26KO mice than in wild-type mice. The alloknesis score in CD26KO mice was significantly reduced by the intradermal administration of recombinant DPPIV or naloxone methiodide, a peripheral μ-opioid receptor antagonist, but not by that of mutant DPPIV without enzyme activity. EMs (EM-1 and EM-2), selective ligands for μ-opioid receptors, are substrates for DPPIV. Immunohistochemically, EMs were located in keratinocytes, fibroblasts, and peripheral sensory nerves. Behavioral analyses revealed that EMs preferentially provoked mechanical alloknesis over chemical itch. DPPIV-digested forms of EMs did not induce mechanical alloknesis. CONCLUSION The present results suggest that EMs induce mechanical alloknesis at the periphery under the enzymatic control of CD26/DPPIV.
Collapse
Affiliation(s)
- Eriko Komiya
- Juntendo Itch Research Center, Institute for Environmental and Gender-Specific Medicine, Graduate School of Medicine, Juntendo University, Chiba, Japan
| | - Mitsutoshi Tominaga
- Juntendo Itch Research Center, Institute for Environmental and Gender-Specific Medicine, Graduate School of Medicine, Juntendo University, Chiba, Japan; Anti-Aging Skin Research Laboratory, Graduate School of Medicine, Juntendo University, Chiba, Japan
| | - Ryo Hatano
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Yuji Kamikubo
- Department of Pharmacology, Juntendo University School of Medicine, Tokyo, Japan
| | - Sumika Toyama
- Juntendo Itch Research Center, Institute for Environmental and Gender-Specific Medicine, Graduate School of Medicine, Juntendo University, Chiba, Japan
| | - Hakushun Sakairi
- Department of Pharmacology, Juntendo University School of Medicine, Tokyo, Japan
| | - Kotaro Honda
- Juntendo Itch Research Center, Institute for Environmental and Gender-Specific Medicine, Graduate School of Medicine, Juntendo University, Chiba, Japan
| | - Takumi Itoh
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan; Atopy (Allergy) Research Center, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Yayoi Kamata
- Juntendo Itch Research Center, Institute for Environmental and Gender-Specific Medicine, Graduate School of Medicine, Juntendo University, Chiba, Japan; Anti-Aging Skin Research Laboratory, Graduate School of Medicine, Juntendo University, Chiba, Japan
| | - Munehiro Tsurumachi
- Juntendo Itch Research Center, Institute for Environmental and Gender-Specific Medicine, Graduate School of Medicine, Juntendo University, Chiba, Japan; Department of Dermatology, Juntendo University Urayasu Hospital, Chiba, Japan
| | - Ryoma Kishi
- Juntendo Itch Research Center, Institute for Environmental and Gender-Specific Medicine, Graduate School of Medicine, Juntendo University, Chiba, Japan; Department of Dermatology, Juntendo University Urayasu Hospital, Chiba, Japan
| | - Kei Ohnuma
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Takashi Sakurai
- Department of Pharmacology, Juntendo University School of Medicine, Tokyo, Japan
| | - Chikao Morimoto
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Kenji Takamori
- Juntendo Itch Research Center, Institute for Environmental and Gender-Specific Medicine, Graduate School of Medicine, Juntendo University, Chiba, Japan; Anti-Aging Skin Research Laboratory, Graduate School of Medicine, Juntendo University, Chiba, Japan; Department of Dermatology, Juntendo University Urayasu Hospital, Chiba, Japan.
| |
Collapse
|
3
|
Itoh T, Hatano R, Horimoto Y, Yamada T, Song D, Otsuka H, Shirakawa Y, Mastuoka S, Iwao N, Aune TM, Dang NH, Kaneko Y, Okumura K, Morimoto C, Ohnuma K. IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells. Cell Death Dis 2021; 12:520. [PMID: 34021125 PMCID: PMC8139965 DOI: 10.1038/s41419-021-03787-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2021] [Revised: 05/01/2021] [Accepted: 05/03/2021] [Indexed: 12/12/2022]
Abstract
Triple-negative breast cancer (TNBC) has a poor prognosis compared to other breast cancer subtypes. Although epidermal growth factor receptor (EGFR) is overexpressed in TNBC, clinical trials with EGFR inhibitors including tyrosine kinase inhibitors (EGFR-TKI) in TNBC have heretofore been unsuccessful. To develop effective EGFR-targeted therapy for TNBC, the precise mechanisms of EGFR-TKI resistance in TNBC need to be elucidated. In this study, to understand the molecular mechanisms involved in the differences in EGFR-TKI efficacy on TNBC between human and mouse, we focused on the effect of IL-26, which is absent in mice. In vitro analysis showed that IL-26 activated AKT and JNK signaling of bypass pathway of EGFR-TKI in both murine and human TNBC cells. We next investigated the mechanisms involved in IL-26-mediated EGFR-TKI resistance in TNBC. We identified EphA3 as a novel functional receptor for IL-26 in TNBC. IL-26 induced dephosphorylation and downmodulation of EphA3 in TNBC, which resulted in increased phosphorylation of AKT and JNK against EGFR-TKI-induced endoplasmic reticulum (ER) stress, leading to tumor growth. Meanwhile, the blockade of IL-26 overcame EGFR-TKI resistance in TNBC. Since the gene encoding IL-26 is absent in mice, we utilized human IL-26 transgenic (hIL-26Tg) mice as a tumor-bearing murine model to characterize the role of IL-26 in the differential effect of EGFR-TKI in human and mice and to confirm our in vitro findings. Our findings indicate that IL-26 activates the bypass pathway of EGFR-TKI, while blockade of IL-26 overcomes EGFR-TKI resistance in TNBC via enhancement of ER stress signaling. Our work provides novel insights into the mechanisms of EGFR-TKI resistance in TNBC via interaction of IL-26 with its newly identified receptor EphA3, while also suggesting IL-26 as a possible therapeutic target in TNBC.
Collapse
Affiliation(s)
- Takumi Itoh
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.,Atopy (Allergy) Research Center, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan
| | - Ryo Hatano
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan
| | - Yoshiya Horimoto
- Department of Breast Oncology, School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan
| | - Taketo Yamada
- Department of Pathology, Saitama Medical University, 38 Morohongo, Moroyama-machi, Iruma-gun, Saitama, 350-0495, Japan.,Department of Pathology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Dan Song
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan
| | - Haruna Otsuka
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan
| | - Yuki Shirakawa
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan
| | - Shuji Mastuoka
- Department of Immunological Diagnosis, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan
| | - Noriaki Iwao
- Department of Hematology, Juntendo University Shizuoka Hospital, 1129 Nagaoka, Izunokuni, Shizuoka, 410-2295, Japan
| | - Thomas M Aune
- Department of Medicine, Vanderbilt University School of Medicine, Vanderbilt University Medical Center, Nashville, TN, 37232, USA
| | - Nam H Dang
- Division of Hematology/Oncology, University of Florida, 1600 SW Archer Road-Box 100278, Room MSB M410A, Gainesville, FL, 32610, USA
| | - Yutaro Kaneko
- Y's AC Co., Ltd., 2-6-8 Kudanminami, Chiyoda-ku, Tokyo, 102-0074, Japan
| | - Ko Okumura
- Atopy (Allergy) Research Center, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan
| | - Chikao Morimoto
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan
| | - Kei Ohnuma
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
| |
Collapse
|
4
|
Itoh T, Toda N, Osaki T, Maegawa Y, Yoshizawa R, Ishikawa Y, Nishiyama O, Yoshizawa M, Nakajima S, Nakamura M, Morino Y. Impact of east Japan earthquake disaster with massive tsunami for prevalence of Takotsubo syndrome – a multicenter regional registry before and after east Japan earthquake disaster. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1813] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Previous studies demonstrated Takotsubo syndrome (TS) was easy provoked by earthquake disaster. However, a previous other regional report demonstrated TS was not increased after 2011 east Japan earthquake disaster. The purpose of this study was to clarify incidence of TS after the earthquake disaster in Iwate prefecture during long term period.
Method
Consecutive hospitalized TS patients were registered during 8 years between 2009 and 2016 in our medical university and five Iwate prefecture hospitals. Moreover, patients were divided into two groups, i.e., those with the inland and those with tsunami-stricken area groups. Prevalence of TS were calculated by standard incidence ratio (SIR) before and after the earthquake disaster. Moreover, long-term prognosis in the both groups was compared using Kaplan-Meier analysis.
Results
A total of 112 TS (male 25 and female 87) were registered from acute coronary syndrome registry in each hospital (n=4,163). Averaged age was 75.3 year-old. A total number of TS just after the two months of the earthquake (March and April 2011) was nine and significance monthly variation was observed comparing with the other months (p=0.029). SIR before and after the disaster is as following Figure. There were no significant differences for long-term prognosis between the two groups (p=0.20).
Conclusion
Incidence of TS was increased in acute phase after east Japan earthquake disaster. However, significance increases were maintained during long-term period, although number of TS was decreased after acute phase. TS is increased not only acute but also chronic phase after the serious earthquake disaster.
Standard incidence ratio
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- T Itoh
- Division of Cardiology, Department of Internal Medicine, Memorial Heart Center, Iwate Medical Univ., Morioka, Japan
| | - N Toda
- Iwate Medical University, Morioka, Japan
| | - T Osaki
- Iwate Prefecture Kuji Hospital, Department of Cardiology, Kuji, Japan
| | - Y Maegawa
- Iwate prefecture Kuji Hospital, Department of Cardiology, Kuji, Japan
| | - R Yoshizawa
- Iwate Prefecture Kamaishi Hospital, Department of Cardiology, Kamaishi, Japan
| | - Y Ishikawa
- Division of Cardiology, Department of Internal Medicine, Memorial Heart Center, Iwate Medical Univ., Morioka, Japan
| | - O Nishiyama
- Iwate Prefecture Ninohe Hospital, Ninohe, Japan
| | - M Yoshizawa
- Division of Cardiology, Department of Internal Medicine, Memorial Heart Center, Iwate Medical Univ., Morioka, Japan
| | - S Nakajima
- Division of Cardiology, Department of Internal Medicine, Memorial Heart Center, Iwate Medical Univ., Morioka, Japan
| | - M Nakamura
- Iwate Medical University, Morioka, Japan
| | - Y Morino
- Division of Cardiology, Department of Internal Medicine, Memorial Heart Center, Iwate Medical Univ., Morioka, Japan
| |
Collapse
|
5
|
Ashina S, Sakai A, Masuda A, Tsujimae M, Kobayashi T, Shiomi Y, Shiomi H, Kanaji S, Itoh T, Kakeji Y, Kodama Y. Gastrointestinal: Gastric outlet obstruction caused by a hamartomatous inverted polyp and an ectopic pancreas. J Gastroenterol Hepatol 2020; 35:1667. [PMID: 32285468 DOI: 10.1111/jgh.15054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/27/2020] [Accepted: 03/25/2020] [Indexed: 12/09/2022]
Affiliation(s)
- S Ashina
- Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine
| | - A Sakai
- Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine
| | - A Masuda
- Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine
| | - M Tsujimae
- Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine
| | - T Kobayashi
- Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine
| | - Y Shiomi
- Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine
| | - H Shiomi
- Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine
| | - S Kanaji
- Division of Gastrointestinal Surgery, Department of Surgery, Kobe University Graduate School of Medicine
| | - T Itoh
- Division of Diagnostic Pathology, Kobe University Graduate School of Medicine
| | - Y Kakeji
- Division of Gastrointestinal Surgery, Department of Surgery, Kobe University Graduate School of Medicine
| | - Y Kodama
- Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine
| |
Collapse
|
6
|
Whiteside GT, Hummel M, Knappenberger T, Hiroyama S, Itoh T, Takai N, Kyle DJ. 0001 Activation of Nociceptin/Orphanin-FQ Peptide (NOP) Receptors Produces an Increase in Non-REM Sleep in Rats and Constitutes a Novel and Attractive Target for the Treatment of Insomnia. Sleep 2020. [DOI: 10.1093/sleep/zsaa056.000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Treatments for insomnia have targeted GABA, histamine, serotonin, melatonin and orexin receptors. The nociceptin/orphanin-FQ peptide (NOP) receptor is widely expressed in the nervous system. High doses of NOP agonists administered systemically or locally into the CNS can result in sedation, however, the utility of targeting this receptor to treat insomnia has not been fully described.
Methods
V117957 is a recently described investigational oral, potent and selective NOP receptor partial agonist. We determined the brain Kp in whole brain and multiple sub-regions (50mg/kg) and receptor occupancy in the hypothalamus (30, 300mg/kg) via in vivo displacement using [3H]-NOP-1A. EEG/EMG were determined in rats chronically implanted with electrodes (cortex and dorsal neck muscle) and recorded via telemetry following dosing (3, 30, 300mg/kg); sleep stage was determined from visual analysis of EEG level. Sleep parameters were also assessed in NOP receptor knock-out rats (300mg/kg). The side-effect profile for V117957 was determined by functional observation battery, whole-body plethysmography, Morris water maze (MWM) (up to 600mg/kg) and conditioned place preference (CPP) assay (up to 300mg/kg).
Results
V117957 displayed limited distribution into the CNS but achieved a high level of receptor occupancy (75% at 30mg/kg). Administration of V117957 produced dose-dependent and statistically significant increases in non-REM sleep with a minimally efficacious dose of 30mg/kg; a coincident dose-dependent and statistically significant decrease in wakefulness and a non-dose-dependent effect on REM sleep occurred. These changes were not seen in knock-out animals demonstrating effects are via NOP receptors. At doses higher than those that increased non-REM sleep, V117957 had no effects in a functional observational battery, did not affect escape latency in MWM or produce CPP; additionally, V117957 did not affect respiratory parameters.
Conclusion
We conclude that activation of NOP receptors decreases wakefulness and increases non-REM sleep in rats with an improved preclinical profile compared to historical profiles of current treatments and, therefore, may represent a novel and attractive target for the treatment of insomnia.
Support
Funded by Shionogi and Imbrium Therapeutics, a subsidiary of Purdue Pharma L.P.
Collapse
Affiliation(s)
| | - M Hummel
- Purdue Pharma L.P., Stamford, CT
| | | | | | - T Itoh
- Shionogi & Co., Ltd., Osaka, JAPAN
| | - N Takai
- Shionogi & Co., Ltd., Osaka, JAPAN
| | - D J Kyle
- Purdue Pharma L.P., Stamford, CT
| |
Collapse
|
7
|
Mori H, Nishihara K, Honda S, Kojima S, Takegami M, Takahashi J, Itoh T, Watanabe T, Takenaka T, Ito M, Takayama M, Kario K, Sumiyoshi T, Kimura K, Yasuda S. P3615The number of coronary risk factors and mortality in patients with acute myocardial infarction from Japanese nation-wide real-world database. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Hypertension, diabetes, dyslipidemia and smoking are so-called coronary risk factors for coronary heart disease, which were established by extensive epidemiological research. However, in Japanese patients with acute myocardial infarction (AMI), the impact of number of coronary risk factors on in-hospital morality has not been elucidated.
Methods
The Japan Acute Myocardial Infarction Registry (JAMIR) is a nationwide real-world database integrated form 10 regional registries. We examined the association between number of coronary risk factors and in-hospital mortality from this JAMIR registry.
Results
The data were obtained from total of 20462 AMI patients (mean age, 68.8±13.3 years old; 15281 men, 5181 women). Figure 1 shows the prevalence of each coronary risk factors stratified by sex and decade. The prevalence of hypertension became higher with the advanced age while the prevalence of smoking became lower with the advanced age. Prevalence of diabetes and dyslipidemia were highest in middle age. Majority (76.9%) of the patients with AMI had at least 1 of these coronary risk factors and, 23.1% had none of them. Overall, except women under 50, number of coronary risk factor was relatively less in older age (Figure 2). In-hospital mortality by sex and decades was shown in figure 3. In-hospital mortality rates were 10.7%, 10.5%, 7.2%, 5.0% and 4.5% with 0, 1, 2, 3 and 4 risk factors, respectively (Figure 4A). After adjusting age and sex, there was an inverse association between the number of coronary risk factors and in-hospital mortality (adjusted odds ratio [1.68; 95% CI, 1.20–2.35] among individuals with 0 vs. 4 risk factors, Figure 4B).
Conclusion
In the present study of Japanese patients with AMI, who received modern medical treatment, in-hospital mortality was inversely related to the number of coronary risk factors.
Acknowledgement/Funding
Grant-in-Aid for Scientific Research
Collapse
Affiliation(s)
- H Mori
- Fujigaoka Hospital, Yokohama, Japan
| | - K Nishihara
- Miyazaki Medical Association Hospital, Miyazaki, Japan
| | - S Honda
- National Cerebral and Cardiovascular Center, Osaka, Japan
| | - S Kojima
- Kawasaki Medical University, Okayama, Japan
| | - M Takegami
- Kawasaki Medical University, Okayama, Japan
| | | | - T Itoh
- Iwate Medical University, Morioka, Japan
| | | | | | - M Ito
- Mie University, Tsu, Japan
| | - M Takayama
- Sakakibara Heart Institute, Tokyo, Japan
| | - K Kario
- Jichi Medical University, Tochigi, Japan
| | | | - K Kimura
- Yokohama City University Medical Center, Yokohama, Japan
| | - S Yasuda
- Yokohama City University Medical Center, Yokohama, Japan
| |
Collapse
|
8
|
Minami K, Tanaka Y, Okamoto T, Shimizu N, Doi T, Ogawa H, Hokka D, Jimbo N, Nishio W, Yoshimura M, Itoh T, Maniwa Y. EP1.12-17 Neuroendocrine Marker Staining Pattern Categorization of Small-Sized Pulmonary Large Cell Neuroendocrine Carcinoma. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.2262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
9
|
Hatano R, Itoh T, Otsuka H, Okamoto S, Komiya E, Iwata S, Aune TM, Dang NH, Kuwahara-Arai K, Ohnuma K, Morimoto C. Characterization of novel anti-IL-26 neutralizing monoclonal antibodies for the treatment of inflammatory diseases including psoriasis. MAbs 2019; 11:1428-1442. [PMID: 31397631 DOI: 10.1080/19420862.2019.1654305] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Interleukin (IL)-26, known as a Th17 cytokine, acts on various cell types and has multiple biological functions. Although its precise role still remains to be elucidated, IL-26 is suggested to be associated with the pathology of diverse chronic inflammatory diseases such as psoriasis, inflammatory bowel diseases and rheumatoid arthritis. To develop novel neutralizing anti-human IL-26 monoclonal antibodies (mAbs) for therapeutic use in the clinical setting, we immunized mice with human IL-26 protein. Hybridomas producing anti-IL-26 mAbs were screened for various in vitro functional assays, STAT3 phosphorylation and antibiotic assays. Although the IL-20RA/IL-10RB heterodimer is generally believed to be the IL-26 receptor, our data strongly suggest that both IL-20RA-dependent and -independent pathways are involved in IL-26-mediated stimulation. We also investigated the potential therapeutic effect of anti-IL-26 mAbs in the imiquimod-induced psoriasis-like murine model using human IL-26 transgenic mice. These screening methods enabled us to develop novel neutralizing anti-human IL-26 mAbs. Importantly, administration of IL-26-neutralizing mAb did not have an effect on the antimicrobial activity of IL-26. Taken together, our data strongly suggest that our newly developed anti-human IL-26 mAb is a potential therapeutic agent for the treatment of diverse chronic inflammatory diseases including psoriasis.
Collapse
Affiliation(s)
- Ryo Hatano
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University , Tokyo , Japan
| | - Takumi Itoh
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University , Tokyo , Japan
| | - Haruna Otsuka
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University , Tokyo , Japan
| | - Sayo Okamoto
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University , Tokyo , Japan
| | - Eriko Komiya
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University , Tokyo , Japan.,Institute for Environmental and Gender Specific Medicine, Juntendo University Graduate School of Medicine , Urayasu , Japan
| | - Satoshi Iwata
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University , Tokyo , Japan
| | - Thomas M Aune
- Department of Medicine, Vanderbilt University School of Medicine, Vanderbilt University Medical Center , Nashville , TN , USA
| | - Nam H Dang
- Division of Hematology/Oncology, University of Florida , Gainesville , FL , USA
| | - Kyoko Kuwahara-Arai
- Department of Microbiology, Juntendo University School of Medicine , Tokyo , Japan
| | - Kei Ohnuma
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University , Tokyo , Japan
| | - Chikao Morimoto
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University , Tokyo , Japan
| |
Collapse
|
10
|
Matsumura Y, Ito Y, Mezawa Y, Sulidan K, Daigo Y, Hiraga T, Mogushi K, Wali N, Suzuki H, Itoh T, Miyagi Y, Yokose T, Shimizu S, Takano A, Terao Y, Saeki H, Ozawa M, Abe M, Takeda S, Okumura K, Habu S, Hino O, Takeda K, Hamada M, Orimo A. Stromal fibroblasts induce metastatic tumor cell clusters via epithelial-mesenchymal plasticity. Life Sci Alliance 2019; 2:2/4/e201900425. [PMID: 31331982 PMCID: PMC6653778 DOI: 10.26508/lsa.201900425] [Citation(s) in RCA: 43] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2019] [Revised: 07/10/2019] [Accepted: 07/10/2019] [Indexed: 12/16/2022] Open
Abstract
This study highlights the cellular and molecular mechanisms by which stromal fibroblasts enable human breast cancer cells to form tumor cell clusters and acquire highly invasive and metastatic traits. Emerging evidence supports the hypothesis that multicellular tumor clusters invade and seed metastasis. However, whether tumor-associated stroma induces epithelial–mesenchymal plasticity in tumor cell clusters, to promote invasion and metastasis, remains unknown. We demonstrate herein that carcinoma-associated fibroblasts (CAFs) frequently present in tumor stroma drive the formation of tumor cell clusters composed of two distinct cancer cell populations, one in a highly epithelial (E-cadherinhiZEB1lo/neg: Ehi) state and another in a hybrid epithelial/mesenchymal (E-cadherinloZEB1hi: E/M) state. The Ehi cells highly express oncogenic cell–cell adhesion molecules, such as carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and CEACAM6 that associate with E-cadherin, resulting in increased tumor cell cluster formation and metastatic seeding. The E/M cells also retain associations with Ehi cells, which follow the E/M cells leading to collective invasion. CAF-produced stromal cell-derived factor 1 and transforming growth factor-β confer the Ehi and E/M states as well as invasive and metastatic traits via Src activation in apposed human breast tumor cells. Taken together, these findings indicate that invasive and metastatic tumor cell clusters are induced by CAFs via epithelial–mesenchymal plasticity.
Collapse
Affiliation(s)
- Yuko Matsumura
- Department of Molecular Pathogenesis, Graduate School of Medicine, Juntendo University, Tokyo, Japan.,Department of Obstetrics and Gynecology, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Yasuhiko Ito
- Department of Molecular Pathogenesis, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Yoshihiro Mezawa
- Department of Molecular Pathogenesis, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Kaidiliayi Sulidan
- Department of Molecular Pathogenesis, Graduate School of Medicine, Juntendo University, Tokyo, Japan.,Department of Obstetrics and Gynecology, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Yataro Daigo
- Center for Antibody and Vaccine Therapy, Research Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.,Department of Medical Oncology and Cancer Center, Shiga University of Medical Science, Otsu, Japan
| | - Toru Hiraga
- Department of Histology and Cell Biology, Matsumoto Dental University, Nagano, Japan
| | - Kaoru Mogushi
- Intractable Disease Research Center, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Nadila Wali
- Department of Molecular Pathogenesis, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Hiromu Suzuki
- Department of Molecular Biology, School of Medicine, Sapporo Medical University, Hokkaido, Japan
| | - Takumi Itoh
- Department of Molecular Pathogenesis, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Yohei Miyagi
- Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, Japan
| | - Tomoyuki Yokose
- Department of Pathology, Kanagawa Cancer Center, Yokohama, Japan
| | - Satoru Shimizu
- Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, Japan
| | - Atsushi Takano
- Center for Antibody and Vaccine Therapy, Research Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.,Department of Medical Oncology and Cancer Center, Shiga University of Medical Science, Otsu, Japan
| | - Yasuhisa Terao
- Department of Obstetrics and Gynecology, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Harumi Saeki
- Department of Molecular Pathogenesis, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Masayuki Ozawa
- Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
| | - Masaaki Abe
- Department of Molecular Pathogenesis, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Satoru Takeda
- Department of Obstetrics and Gynecology, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Ko Okumura
- Atopy Research Center, Biomedical Research Center, Graduate School of Medicine, Juntendo University, Tokyo, Japan.,Department of Biofunctional Microbiota, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Sonoko Habu
- Atopy Research Center, Biomedical Research Center, Graduate School of Medicine, Juntendo University, Tokyo, Japan.,Department of Biofunctional Microbiota, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Okio Hino
- Department of Molecular Pathogenesis, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Kazuyoshi Takeda
- Division of Cell Biology, Biomedical Research Center, Graduate School of Medicine, Juntendo University, Tokyo, Japan.,Department of Biofunctional Microbiota, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Michiaki Hamada
- Department of Electrical Engineering and Bioscience, Faculty of Science and Engineering, Waseda University, Tokyo, Japan
| | - Akira Orimo
- Department of Molecular Pathogenesis, Graduate School of Medicine, Juntendo University, Tokyo, Japan .,Cancer Research (CR)-UK Stromal-Tumor Interaction Group, Paterson Institute for Cancer Research, The University of Manchester, Manchester, UK
| |
Collapse
|
11
|
Hatano R, Yamada T, Madokoro H, Otsuka H, Komiya E, Itoh T, Narita Y, Iwata S, Yamazaki H, Matsuoka S, Dang NH, Ohnuma K, Morimoto C. Development of novel monoclonal antibodies with specific binding affinity for denatured human CD26 in formalin-fixed paraffin-embedded and decalcified specimens. PLoS One 2019; 14:e0218330. [PMID: 31194830 PMCID: PMC6564021 DOI: 10.1371/journal.pone.0218330] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2019] [Accepted: 05/30/2019] [Indexed: 11/19/2022] Open
Abstract
A 110-kDa type II transmembrane glycoprotein with dipeptidyl peptidase IV (DPPIV) activity in its extracellular region, CD26 has a multitude of biological functions and plays an important role in the regulation of inflammatory responses and tumor biology. Our work has focused on CD26 as a novel therapeutic target for various tumors and immune disorders, and we have recently developed a humanized anti-CD26 monoclonal antibody (mAb), YS110, which has promising safety profile and clinical activity in patients with malignant pleural mesothelioma. The development of an anti-human CD26 mAb that can clearly and reliably detect the denatured CD26 molecule in formalin-fixed paraffin-embedded (FFPE) tissues in the clinical setting is therefore of the utmost importance. To develop novel anti-CD26 mAbs capable of binding to denatured CD26, we immunized mice with urea-treated CD26 protein. Hybridoma supernatants were screened for specific reactivity with human CD26 by immunostaining through the use of a set of FFPE human CD26-positive or negative tumor cell lines. This screening method enables us to develop novel anti-human CD26 mAbs suitable for immunohistochemical staining of CD26 in FFPE non-tumor and tumor tissue sections with reliable clarity and intensity. Specifically, these mAbs display strong binding affinity to denatured human CD26 rather than undenatured human CD26, and are capable of detecting denatured human CD26 in decalcified specimens. These novel anti-CD26 mAbs are potentially useful for the analysis of CD26 expression in cancer patients with bony metastasis, and may help decide the appropriateness of YS110 therapy for future cancer patients.
Collapse
Affiliation(s)
- Ryo Hatano
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Hongo, Bunkyo-ku, Tokyo, Japan
| | - Taketo Yamada
- Department of Pathology, Saitama Medical University, Moroyama-machi, Iruma-gun, Saitama, Japan
- Department of Pathology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan
| | - Hiroko Madokoro
- Department of Pathology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan
| | - Haruna Otsuka
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Hongo, Bunkyo-ku, Tokyo, Japan
| | - Eriko Komiya
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Hongo, Bunkyo-ku, Tokyo, Japan
| | - Takumi Itoh
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Hongo, Bunkyo-ku, Tokyo, Japan
| | - Yuka Narita
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Hongo, Bunkyo-ku, Tokyo, Japan
| | - Satoshi Iwata
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Hongo, Bunkyo-ku, Tokyo, Japan
| | - Hiroto Yamazaki
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Hongo, Bunkyo-ku, Tokyo, Japan
| | - Shuji Matsuoka
- Department of Immunological Diagnosis, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo, Japan
| | - Nam H. Dang
- Division of Hematology/Oncology, University of Florida, Gainesville, FL, United States of America
| | - Kei Ohnuma
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Hongo, Bunkyo-ku, Tokyo, Japan
| | - Chikao Morimoto
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Hongo, Bunkyo-ku, Tokyo, Japan
- * E-mail:
| |
Collapse
|
12
|
Itoh T, Hatano R, Komiya E, Otsuka H, Narita Y, Aune TM, Dang NH, Matsuoka S, Naito H, Tominaga M, Takamori K, Morimoto C, Ohnuma K. Biological Effects of IL-26 on T Cell–Mediated Skin Inflammation, Including Psoriasis. J Invest Dermatol 2019; 139:878-889. [DOI: 10.1016/j.jid.2018.09.037] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2018] [Revised: 09/25/2018] [Accepted: 09/26/2018] [Indexed: 12/20/2022]
|
13
|
Okamura S, Osaki T, Nishimura K, Ohsaki H, Shintani M, Matsuoka H, Maeda K, Shiogama K, Itoh T, Kamoshida S. Thymidine kinase-1/CD31 double immunostaining for identifying activated tumor vessels. Biotech Histochem 2018; 94:60-64. [DOI: 10.1080/10520295.2018.1499962] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Affiliation(s)
- S. Okamura
- Laboratory of Pathology, Department of Medical Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan
| | - T. Osaki
- Laboratory of Pathology, Department of Medical Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan
| | - K. Nishimura
- Laboratory of Pathology, Department of Medical Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan
| | - H. Ohsaki
- Laboratory of Pathology, Department of Medical Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan
| | - M. Shintani
- Department of Medical Technology, Kobe Tokiwa University, Japan
| | - H. Matsuoka
- Department of Surgery, Fujita Health University School of Medicine
| | - K. Maeda
- Department of Surgery, Fujita Health University School of Medicine
| | - K. Shiogama
- Department of Morphology and Cell Function, Fujita Health University School of Health Sciences, Toyoake, Japan
| | - T. Itoh
- Department of Diagnostic Pathology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - S. Kamoshida
- Laboratory of Pathology, Department of Medical Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan
| |
Collapse
|
14
|
Sekine Y, Itoh T, Toyoda T, Kaiho D, Hoshino H, Oheda H, Koh E. P2.16-39 The Application of 3D Medical Image Analyzer and a Fluorescence Guided Surgery for Pulmonary Sublobar Resection. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1514] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
15
|
Murakami T, Ikari Y, Taniai S, Ishibashi Y, Taguchi I, Ako J, Kyono H, Yoshizawa M, Itoh T, Morino Y, Kato R, Sakuma M, Sugimura H, Akashi Y, Yoshino H. P4393The clinical characteristics of mortality in patients with Takotsubo Syndrome during hospitalization-A Multicenter Registry in Eight-University Hospitals in East Japan. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p4393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
| | - Y Ikari
- Tokai University, Kanagawa, Japan
| | | | | | - I Taguchi
- Dokkyo Medical University Koshigya Hospital, Koshigaya City, Japan
| | - J Ako
- Kitasato University School of Medicine, Kanagawa, Japan
| | - H Kyono
- Teikyo University, Tokyo, Japan
| | | | - T Itoh
- Iwate University Hospital, Iwate, Japan
| | - Y Morino
- Iwate University Hospital, Iwate, Japan
| | - R Kato
- Saitama Medical University, Saitama, Japan
| | - M Sakuma
- Dokkyo Medical University, tochigi, Japan
| | - H Sugimura
- Dokkyo Medical University Nikko Medical Center, Tochigi, Japan
| | - Y Akashi
- St. Marianna University, Kawasaki, Japan
| | | |
Collapse
|
16
|
Hirai T, Yamaga R, Fujita A, Itoh T. Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments. J Clin Pharm Ther 2018; 43:829-835. [PMID: 29908131 DOI: 10.1111/jcpt.12720] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2018] [Accepted: 05/14/2018] [Indexed: 12/19/2022]
Abstract
WHAT IS KNOWN AND OBJECTIVE Angiotensin converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) represent the cornerstones of hypertension and congestive heart failure treatment. Risk factors for hyperkalaemia associated with ACEI and ARB are chronic kidney disease and concomitant medications which increase serum potassium level. Body mass index (BMI) also affects pharmacokinetics of ACEI and ARB and potassium disposition. We evaluated the relationship between BMI and hyperkalaemia associated with ACEI and ARB treatments. METHODS Study design is a retrospective case-control analysis. Patients who had been prescribed ACEI or ARB between June 2015 and June 2017 at Tokyo Women's Medical University, Medical Center East, were included. Patient clinical background was collected from medical records. Hyperkalaemia was defined as serum potassium above 5.5 meq/L. The concomitant use of ACEI and ARB, aldosterone antagonists, direct renin inhibitor, sulfamethoxazole-trimethoprim and non-steroidal anti-inflammatory drugs (NSAIDs) was regarded as hyperkalaemia-inducing medications. The relationship between BMI and hyperkalaemia associated with ACEI and ARB treatments was assessed using multivariable logistic regression analysis. RESULTS AND DISCUSSION The study included 2987 patients aged 70.1 ± 12.9 years, 61.0% were men, and BMI was 23.8 ± 4.4 kg/m2 . The incidence of hyperkalaemia was 7.8%. Multivariable logistic regression analysis revealed that age >65 years, low BMI, diabetes, history of treatment for hyperkalaemia, serum sodium <135 meq/L, eGFR <30 mL/min/1.73m2 and the concomitant use of hyperkalaemia-inducing medications were independent risk factors for hyperkalaemia associated with ACEI and ARB. WHAT IS NEW AND CONCLUSION This study demonstrated that BMI provides useful information for the identification of potential risk for hyperkalaemia associated with ACEI and ARB treatments.
Collapse
Affiliation(s)
- T Hirai
- Department of Pharmacy, Tokyo Women's Medical University Medical Center East, Tokyo, Japan
| | - R Yamaga
- Department of Pharmacy, Tokyo Women's Medical University Medical Center East, Tokyo, Japan
| | - A Fujita
- Department of Pharmacy, Tokyo Women's Medical University Medical Center East, Tokyo, Japan
| | - T Itoh
- Department of Pharmacy, Tokyo Women's Medical University Medical Center East, Tokyo, Japan
| |
Collapse
|
17
|
Ohnuma K, Hatano R, Komiya E, Otsuka H, Itoh T, Iwao N, Kaneko Y, Yamada T, Dang NH, Morimoto C. A novel role for CD26/dipeptidyl peptidase IV as a therapeutic target. Front Biosci (Landmark Ed) 2018; 23:1754-1779. [PMID: 29772527 DOI: 10.2741/4671] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
CD26 is a 110 kDa surface glycoprotein with intrinsic dipeptidyl peptidase IV activity that is expressed on numerous cell types and has a multitude of biological functions. The role of CD26 in immune regulation has been extensively characterized, with recent findings elucidating its linkage with signaling pathways and structures involved in T-lymphocyte activation as well as antigen presenting cell-T-cell interaction. In this paper, we will review emerging data on CD26-mediated immune regulation suggesting that CD26 may be an appropriate therapeutic target for the treatment of selected immune disorders as well as Middle East respiratory syndrome coronavirus. Moreover, we have had a long-standing interest in the role of CD26 in cancer biology and its suitability as a novel therapeutic target in selected neoplasms. We reported robust in vivo data on the anti-tumor activity of anti-CD26 monoclonal antibody in mouse xenograft models. We herein review significant novel findings and the early clinical development of a CD26-targeted therapy in selected immune disorders and cancers, advances that can lead to a more hopeful future for patients with these intractable diseases.
Collapse
Affiliation(s)
- Kei Ohnuma
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan,
| | - Ryo Hatano
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
| | - Eriko Komiya
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
| | - Haruna Otsuka
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
| | - Takumi Itoh
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
| | - Noriaki Iwao
- Department of Hematology, Juntendo University Shizuoka Hospital, Nagaoka 1129, Izunokuni-city, Shizuoka 410-2295, Japan
| | - Yutaro Kaneko
- Y's AC Co., Ltd., 5-3-14, Toranomon, Minato-ku, Tokyo 105-0001, Japan
| | - Taketo Yamada
- Department of Pathology, Keio University school of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
| | - Nam H Dang
- Division of Hematology/Oncology, University of Florida, 1600 SW Archer Road-Box 100278, Room MSB M410A, Gainesville, FL 32610, U.S.A
| | - Chikao Morimoto
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
| |
Collapse
|
18
|
Fukumoto K, Onitsuka T, Itoh T, Sakasegawa H, Tanigawa H. Microstructure of fatigue-tested F82H steel under multi-axial loadings. Nuclear Materials and Energy 2018. [DOI: 10.1016/j.nme.2018.04.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
19
|
Abstract
A special lung support technique is required during carina! or tracheal surgery. Veno venous extracorporeal membrane oxygenation (ECMO) has become an accepted techinique for temporary lung support. Therefore, the purpose of our experiments was to evaluate the effect of veno venous ECMO (veno-right ventricle bypass) without ventilatory support. In five mongrel dogs, two venous drainage cannula were inserted into the superior vena cava through the right jugular vein and the inferior vena cava through the right femoral vein. In addition, a venous return cannula was inserted into the right ventricle (RV) through the right jugular vein. The veno-right ventricle (veno-RV) bypass system was composed of a centrifugal pump and membrane oxygenator; pump flow was maintained at 88 ± 14 ml/kg/min. Excellent hemodynamics and good oxygenation were obtained. On the basis of these results, we conclude that veno-RV bypass may be used as lung support during pulmonary surgery even though the native lung is not ventilated during the veno-RV bypass procedure.
Collapse
Affiliation(s)
- K. Horita
- Department of Thoracic and Cardiovascular Surgery, Saga Medical School, Saga - Japan
| | - Z.L. Cao
- Department of Thoracic and Cardiovascular Surgery, Saga Medical School, Saga - Japan
| | - T. Itoh
- Department of Thoracic and Cardiovascular Surgery, Saga Medical School, Saga - Japan
| |
Collapse
|
20
|
Itoh T, Kawahira H, Nakashima H, Yata N. Deep learning analyzes Helicobacter pylori infection by upper gastrointestinal endoscopy images. Endosc Int Open 2018; 6:E139-E144. [PMID: 29399610 PMCID: PMC5794437 DOI: 10.1055/s-0043-120830] [Citation(s) in RCA: 117] [Impact Index Per Article: 19.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/12/2017] [Accepted: 09/22/2017] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND AND STUDY AIMS Helicobacter pylori (HP)-associated chronic gastritis can cause mucosal atrophy and intestinal metaplasia, both of which increase the risk of gastric cancer. The accurate diagnosis of HP infection during routine medical checks is important. We aimed to develop a convolutional neural network (CNN), which is a machine-learning algorithm similar to deep learning, capable of recognizing specific features of gastric endoscopy images. The goal behind developing such a system was to detect HP infection early, thus preventing gastric cancer. PATIENTS AND METHODS For the development of the CNN, we used 179 upper gastrointestinal endoscopy images obtained from 139 patients (65 were HP-positive: ≥ 10 U/mL and 74 were HP-negative: < 3 U/mL on HP IgG antibody assessment). Of the 179 images, 149 were used as training images, and the remaining 30 (15 from HP-negative patients and 15 from HP-positive patients) were set aside to be used as test images. The 149 training images were subjected to data augmentation, which yielded 596 images. We used the CNN to create a learning tool that would recognize HP infection and assessed the decision accuracy of the CNN with the 30 test images by calculating the sensitivity, specificity, and area under the receiver operating characteristic (ROC) curve (AUC). RESULTS The sensitivity and specificity of the CNN for the detection of HP infection were 86.7 % and 86.7 %, respectively, and the AUC was 0.956. CONCLUSIONS CNN-aided diagnosis of HP infection seems feasible and is expected to facilitate and improve diagnosis during health check-ups.
Collapse
Affiliation(s)
- Takumi Itoh
- Department of Medical System Engineering, Graduate School of Engineering, Chiba University
| | - Hiroshi Kawahira
- Center for Frontier Medical Engineering, Chiba University, Chiba, Japan,Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan,Corresponding author Hiroshi Kawahira, MD, PhD Chiba University, Center for Frontier Medical Engineering1-33, Yayoi-choInage-ku, Chiba 263-8522Japan+81432903124
| | - Hirotaka Nakashima
- Department of Gastroenterology, Foundation for Detection of Early Gastric Carcinoma, Tokyo, Japan
| | - Noriko Yata
- Department of Information Processing and Computer Science, Graduate School of Advanced Integration Science, Chiba University, Chiba, Japan
| |
Collapse
|
21
|
Nokami T, Yamashita T, Komura T, Handa N, Shimizu M, Yamaguchi K, Domi Y, Usui H, Sakaguchi H, Itoh T. Effects of the ether oxygen atom in alkyl side chains on the physical properties of piperidinium ionic liquids. Faraday Discuss 2018; 206:523-534. [DOI: 10.1039/c7fd00142h] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Various types of piperidinium ionic liquids equipped with an oxygen atom-containing alkyl side chain on the positively charged nitrogen atom were systematically synthesized and their physical properties investigated.
Collapse
|
22
|
Ohnuma K, Hatano R, Itoh T, Iwao N, Dang NH, Morimoto C. Role of IL-26+CD26+CD4 T Cells in Pulmonary Chronic Graft-Versus-Host Disease and Treatment with Caveolin-1-Ig Fc Conjugate. Crit Rev Immunol 2017; 36:239-267. [PMID: 28008806 DOI: 10.1615/critrevimmunol.2016018772] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Obliterative bronchiolitis is the primary noninfectious pulmonary complication after allogeneic hematopoietic cell transplantation and the only pathognomonic manifestation of pulmonary chronic graft-versus-host disease (cGVHD). In our recent study, we identified a novel effect of IL-26, which is absent in rodents, on transplant related-obliterative bronchiolitis. Sublethally irradiated NOD/Shi-scidIL2rγnull mice transplanted with human umbilical cord blood gradually exhibited obliterative bronchiolitis with increased collagen deposition and predominant infiltration with human IL-26+CD26+CD4 T cells. Moreover, we showed that IL-26 increased collagen synthesis in fibroblasts in vitro and that collagen contents were increased in a murine GVHD model using IL26 transgenic mice. In vitro analysis demonstrated a significant increase in IL-26 production by CD4 T cells following CD26 costimulation, while immunoglobulin Fc domain fused with the N-terminal of caveolin-1, the ligand for CD26, (Cav-Ig) effectively inhibited production of IL-26. Administration of Cav-Ig before or after onset of GVHD impeded the development of clinical and histologic features of GVHD without interrupting engraftment of donor-derived human cells, with preservation of the graft-versus-leukemia effect. We concluded that cGVHD of the lungs is caused in part by IL-26+CD26+CD4 T cells, and that treatment with Cav-Ig could be beneficial for cGVHD prevention and therapy.
Collapse
Affiliation(s)
- Kei Ohnuma
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
| | - Ryo Hatano
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
| | - Takumi Itoh
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
| | - Noriaki Iwao
- Department of Hematology, Juntendo University Shizuoka Hospital, Nagaoka 1129, Izunokuni-city, Shizuoka 410-2295, Japan
| | - Nam H Dang
- Division of Hematology/Oncology, University of Florida, 1600 SW Archer Road- Box 100278, Room MSB M410A, Gainesville, FL 32610, U.S.A
| | - Chikao Morimoto
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
| |
Collapse
|
23
|
Sakai Y, Ohbayashi C, Yanagita E, Jimbo N, Kajimoto K, Sakuma T, Hirose T, Yoshimura M, Maniwa Y, Itoh T. PRR11 immunoreactivity is a weak prognostic factor in non-mucinous invasive adenocarcinoma of the lung. Pathologica 2017; 109:133-139. [PMID: 29154370] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/07/2023] Open
Abstract
INTRODUCTION Proline-rich protein 11 (PRR11) functions in the progression of cell cycle, and silencing the PRR11 gene in lung cancer cells results in the inhibition of cellular proliferation, cell cycle progression, cell migration, invasion and colony formation. PRR11 may therefore be a therapeutic target in lung cancer. MATERIALS AND METHODS Microarrays of surgical specimens of non-mucinous invasive adenocarcinoma of the lung, from 346 subjects that were not given preoperative therapy, were autoimmunostained with PRR11 and, except for trace and pseudo-positivity, assessed as "positive" at any proportion and intensity. RESULTS PRR11 immunoreactivity demonstrated a tendency to associate with an aggressive phenotype (tumor size, vascular invasion, and adjuvant therapy) and some effect on overall survival (Hazard ratio 1.51). CONCLUSIONS PRR11 may be a weak prognostic indicator of overall survival of patients with non-mucinous invasive adenocarcinoma of the lung.
Collapse
Affiliation(s)
- Y Sakai
- Department of Diagnostic Pathology, Kobe University Hospital, Hyogo, Japan
| | - C Ohbayashi
- Department of Diagnostic Pathology, Nara Medical University, Nara, Japan
| | - E Yanagita
- Department of Diagnostic Pathology, Kobe University Hospital, Hyogo, Japan
| | - N Jimbo
- Department of Diagnostic Pathology, Kobe University Hospital, Hyogo, Japan
| | - K Kajimoto
- Department of Pathology, Hyogo Cancer Center, Hyogo, Japan
| | - T Sakuma
- Department of Pathology, Hyogo Cancer Center, Hyogo, Japan
| | - T Hirose
- Department of Pathology, Hyogo Cancer Center, Hyogo, Japan
- Department of Pathology for Regional Communication, Kobe University Hospital, Hyogo, Japan
| | - M Yoshimura
- Department of Thoracic Surgery, Hyogo Cancer Center, Hyogo, Japan
| | - Y Maniwa
- Department of Thoracic Surgery, Kobe University Hospital, Hyogo, Japan
| | - T Itoh
- Department of Diagnostic Pathology, Kobe University Hospital, Hyogo, Japan
| |
Collapse
|
24
|
Kato M, Itoh T, Sugai H, Kawamura Y, Hayashi T, Nishi M, Tanasec M, Matsuzaki T, Ishida K, Nagamine K. Development of Electrochemical Hydrogen Pump Under Vacuum Condition for a Compact Tritium Gas Recycling System. Fusion Science and Technology 2017. [DOI: 10.13182/fst02-a22707] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- M. Kato
- Tritium Engineering Laboratory, Department of Fusion Engineering Research, Japan Atomic Energy Research Institute (JAERI), Tokai, Naka, Ibaraki 319-1195, Japan
| | - T Itoh
- KAKEN Co., 1044 Horimachi, Mito, Ibaraki 310-0903, Japan
| | - H. Sugai
- Tritium Engineering Laboratory, Department of Fusion Engineering Research, Japan Atomic Energy Research Institute (JAERI), Tokai, Naka, Ibaraki 319-1195, Japan
| | - Y Kawamura
- Tritium Engineering Laboratory, Department of Fusion Engineering Research, Japan Atomic Energy Research Institute (JAERI), Tokai, Naka, Ibaraki 319-1195, Japan
| | - T. Hayashi
- Tritium Engineering Laboratory, Department of Fusion Engineering Research, Japan Atomic Energy Research Institute (JAERI), Tokai, Naka, Ibaraki 319-1195, Japan
| | - M. Nishi
- Tritium Engineering Laboratory, Department of Fusion Engineering Research, Japan Atomic Energy Research Institute (JAERI), Tokai, Naka, Ibaraki 319-1195, Japan
| | - M. Tanasec
- Department of Radiation Research for Environmental and Resources, Takasaki Institute, JAERI, Takasaki, Gunma 370-1292, Japan
| | - T. Matsuzaki
- Muon Science Laboratory, The Institute of Physical and Chemical Research (RIKEN), Wako, Saitama 351-0198, Japan
| | - K. Ishida
- Muon Science Laboratory, The Institute of Physical and Chemical Research (RIKEN), Wako, Saitama 351-0198, Japan
| | - K. Nagamine
- Muon Science Laboratory, The Institute of Physical and Chemical Research (RIKEN), Wako, Saitama 351-0198, Japan
- Meson Science Laboratory, Institute of Material Structure Science, High Energy Accelerator Research Organization (KEK-MSL), Oho, Tsukuba, Ibaraki 305-0801, Japan
| |
Collapse
|
25
|
Ueda S, Nanjou Y, Itoh T, Tatenuma K, Matsuyama M, Watanabe K. Development of Advanced Column Material for Hydrogen Isotope Separation at Room Temperature. Fusion Science and Technology 2017. [DOI: 10.13182/fst02-a22763] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- S. Ueda
- Kaken Co. Ltd. Hori 1044, Ibaraki 310-0903, Japan +81-29-227-4485
| | - Y. Nanjou
- Kaken Co. Ltd. Hori 1044, Ibaraki 310-0903, Japan +81-29-227-4485
| | - T. Itoh
- Kaken Co. Ltd. Hori 1044, Ibaraki 310-0903, Japan +81-29-227-4485
| | - K. Tatenuma
- Kaken Co. Ltd. Hori 1044, Ibaraki 310-0903, Japan +81-29-227-4485
| | - M. Matsuyama
- Hydrogen Isotope Research Center Toyama Univ., Gofuku 3190 Toyama 930-8555, Japan +81-76-445-6926
| | - K. Watanabe
- Hydrogen Isotope Research Center Toyama Univ., Gofuku 3190 Toyama 930-8555, Japan +81-76-445-6926
| |
Collapse
|
26
|
Komiya E, Hatano R, Otsuka H, Itoh T, Yamazaki H, Yamada T, Dang NH, Tominaga M, Suga Y, Kimura U, Takamori K, Morimoto C, Ohnuma K. A possible role for CD26/DPPIV enzyme activity in the regulation of psoriatic pruritus. J Dermatol Sci 2017; 86:212-221. [DOI: 10.1016/j.jdermsci.2017.03.005] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2016] [Revised: 02/22/2017] [Accepted: 03/08/2017] [Indexed: 01/17/2023]
|
27
|
Kuriyama M, Akino N, Ebisawa N, Honda A, Itoh T, Kawai M, Mogaki K, Ohga T, Oohara H, Umeda N, Usui K, Yamamoto M, Yamamoto T, Matsuoka M. Operation and Development on the Positive-Ion Based Neutral Beam Injection System for JT-60 and JT-60U. Fusion Science and Technology 2017. [DOI: 10.13182/fst02-a238] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- M. Kuriyama
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-1 Mukohyama, Naka-machi, Naka-gun, Ibaraki-ken, 311-0193 Japan
| | - N. Akino
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-1 Mukohyama, Naka-machi, Naka-gun, Ibaraki-ken, 311-0193 Japan
| | - N. Ebisawa
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-1 Mukohyama, Naka-machi, Naka-gun, Ibaraki-ken, 311-0193 Japan
| | - A. Honda
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-1 Mukohyama, Naka-machi, Naka-gun, Ibaraki-ken, 311-0193 Japan
| | - T. Itoh
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-1 Mukohyama, Naka-machi, Naka-gun, Ibaraki-ken, 311-0193 Japan
| | - M. Kawai
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-1 Mukohyama, Naka-machi, Naka-gun, Ibaraki-ken, 311-0193 Japan
| | - K. Mogaki
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-1 Mukohyama, Naka-machi, Naka-gun, Ibaraki-ken, 311-0193 Japan
| | - T. Ohga
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-1 Mukohyama, Naka-machi, Naka-gun, Ibaraki-ken, 311-0193 Japan
| | - H. Oohara
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-1 Mukohyama, Naka-machi, Naka-gun, Ibaraki-ken, 311-0193 Japan
| | - N. Umeda
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-1 Mukohyama, Naka-machi, Naka-gun, Ibaraki-ken, 311-0193 Japan
| | - K. Usui
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-1 Mukohyama, Naka-machi, Naka-gun, Ibaraki-ken, 311-0193 Japan
| | - M. Yamamoto
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-1 Mukohyama, Naka-machi, Naka-gun, Ibaraki-ken, 311-0193 Japan
| | - T. Yamamoto
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-1 Mukohyama, Naka-machi, Naka-gun, Ibaraki-ken, 311-0193 Japan
| | - M. Matsuoka
- University of Mie, Department of Technology Education 1515 Kamihama-cho, Tsu-shi, Japan
| |
Collapse
|
28
|
Kuriyama M, Akino N, Ebisawa N, Grisham L, Honda A, Itoh T, Kawai M, Kazawa M, Mogaki K, Ohara Y, Ohga T, Okumura Y, Oohara H, Umeda N, Usui K, Watanabe K, Yamamoto M, Yamamoto T. Operation and Development of the 500-keV Negative-Ion-Based Neutral Beam Injection System for JT-60U. Fusion Science and Technology 2017. [DOI: 10.13182/fst02-a237] [Citation(s) in RCA: 44] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- M. Kuriyama
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, 801-1 Mukohyama Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - N. Akino
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, 801-1 Mukohyama Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - N. Ebisawa
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, 801-1 Mukohyama Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - L. Grisham
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, 801-1 Mukohyama Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - A. Honda
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, 801-1 Mukohyama Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - T. Itoh
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, 801-1 Mukohyama Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - M. Kawai
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, 801-1 Mukohyama Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - M. Kazawa
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, 801-1 Mukohyama Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - K. Mogaki
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, 801-1 Mukohyama Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - Y. Ohara
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, 801-1 Mukohyama Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - T. Ohga
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, 801-1 Mukohyama Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - Y. Okumura
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, 801-1 Mukohyama Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - H. Oohara
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, 801-1 Mukohyama Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - N. Umeda
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, 801-1 Mukohyama Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - K. Usui
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, 801-1 Mukohyama Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - K. Watanabe
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, 801-1 Mukohyama Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - M. Yamamoto
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, 801-1 Mukohyama Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - T. Yamamoto
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, 801-1 Mukohyama Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| |
Collapse
|
29
|
Motojima O, Yamada H, Komori A, Watanabe KY, Mutoh T, Takeiri Y, Ida K, Akiyama T, Asakura N, Ashikawa N, Chikaraishi H, Cooper WA, Emoto M, Fujita T, Fujiwara M, Funaba H, Goncharov P, Goto M, Hamada Y, Higashijima S, Hino T, Hoshino M, Ichimura M, Idei H, Ido T, Ikeda K, Imagawa S, Inagaki S, Isayama A, Isobe M, Itoh T, Itoh K, Kado S, Kalinina D, Kaneba T, Kaneko O, Kato D, Kato T, Kawahata K, Kawashima H, Kawazome H, Kobuchi T, Kondo K, Kubo S, Kumazawa R, Lyon JF, Maekawa R, Mase A, Masuzaki S, Mito T, Matsuoka K, Miura Y, Miyazawa J, More R, Morisaki T, Morita S, Murakami I, Murakami S, Mutoh S, Nagaoka K, Nagasaki K, Nagayama Y, Nakamura Y, Nakanishi H, Narihara K, Narushima Y, Nishimura H, Nishimura K, Nishiura M, Nishizawa A, Noda N, Notake T, Nozato H, Ohdachi S, Ohkubo K, Ohyabu N, Oyama N, Oka Y, Okada H, Osakabe M, Ozaki T, Peterson BJ, Sagara A, Saida T, Saito K, Sakakibara S, Sakamoto M, Sakamoto R, Sasao M, Sato K, Seki T, Shimozuma T, Shoji M, Sudo S, Takagi S, Takahashi Y, Takase Y, Takenaga H, Takeuchi N, Tamura N, Tanaka K, Tanaka M, Toi K, Takahata K, Tokuzawa T, Torii Y, Tsumori K, Watanabe F, Watanabe M, Watanabe T, Watari T, Yamada I, Yamada S, Yamaguchi T, Yamamoto S, Yamazaki K, Yanagi N, Yokoyama M, Yoshida N, Yoshimura S, Yoshimura Y, Yoshinuma M. Review on the Progress of the LHD Experiment. Fusion Science and Technology 2017. [DOI: 10.13182/fst04-a535] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- O. Motojima
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Yamada
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - A. Komori
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Y. Watanabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Mutoh
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Takeiri
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Ida
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Akiyama
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Asakura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Ashikawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Chikaraishi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - W. A. Cooper
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Emoto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Fujita
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Fujiwara
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Funaba
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - P. Goncharov
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Goto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Hamada
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Higashijima
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Hino
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Hoshino
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Ichimura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Idei
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Ido
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Ikeda
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Imagawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Inagaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - A. Isayama
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Isobe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Itoh
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Itoh
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Kado
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - D. Kalinina
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Kaneba
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - O. Kaneko
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - D. Kato
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Kato
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Kawahata
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Kawashima
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Kawazome
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Kobuchi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Kondo
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Kubo
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - R. Kumazawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - J. F. Lyon
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - R. Maekawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - A. Mase
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Masuzaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Mito
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Matsuoka
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Miura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - J. Miyazawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - R. More
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Morisaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Morita
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - I. Murakami
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Murakami
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Mutoh
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Nagaoka
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Nagasaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Nagayama
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Nakamura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Nakanishi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Narihara
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Narushima
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Nishimura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Nishimura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Nishiura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - A. Nishizawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Noda
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Notake
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Nozato
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Ohdachi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Ohkubo
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Ohyabu
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Oyama
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Oka
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Okada
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Osakabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Ozaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - B. J. Peterson
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - A. Sagara
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Saida
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Saito
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Sakakibara
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Sakamoto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - R. Sakamoto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Sasao
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Sato
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Seki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Shimozuma
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Shoji
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Sudo
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Takagi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Takahashi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Takase
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Takenaga
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Takeuchi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Tamura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Tanaka
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Tanaka
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Toi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Takahata
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Tokuzawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Torii
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Tsumori
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - F. Watanabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Watanabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Watanabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Watari
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - I. Yamada
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Yamada
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Yamaguchi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Yamamoto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Yamazaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Yanagi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Yokoyama
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Yoshida
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Yoshimura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Yoshimura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Yoshinuma
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| |
Collapse
|
30
|
Dhakhwa R, Acharya S, Pradhan S, Shrestha SB, Itoh T. Role of S-100 Immunostain as An Auxiliary Diagnostic Aid in Leprosy. JNMA J Nepal Med Assoc 2017; 56:141-144. [PMID: 28598451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/07/2023] Open
Abstract
INTRODUCTION Histopathologic diagnosis of leprosy is difficult when Bacillary Index (BI) is zero and neural involvement are not easily identifiable on routine Hematoxylin and Eosin stain. This study was undertaken to study the role of S-100 immunostaining in demonstrating different patterns of nerve involvement in various types of leprosy. METHODS Thirty one skin biopsies with clinico-histopathologic diagnoses of leprosy over a period of two years were included in the study. Ten cases of non-lepromatous granulomatous dermatoses (including eight cases of lupus vulgaris and two cases of erythema nodosum) were used as controls. Tissue sections from all cases and controls were stained with Hematoxylin and Eosin (H&E) stain, Fite stain and S-100 immunostain. The H&E stained slides were used to study the histopathological features, Fite stained slides for Bacillary Index and S-100 for nerve changes. RESULTS Neural changes could be demonstrated in the entire spectrum of leprosy using S-100 immunostaining. The most common pattern of nerve destruction in the tuberculoid spectrum was fragmented and infiltrated whereas lepromatous spectrum showed mostly fragmented nerve twigs. Intact nerves were not detected in any of the leprosy cases. CONCLUSIONS S-100 immunostain is a useful auxiliary aid to the routine H&E stain in the diagnosis of leprosy especially tuberculoid spectrum and intermediate leprosy.
Collapse
Affiliation(s)
- R Dhakhwa
- Department of Pathology, Kathmandu Medical College, Sinamangal, Kathmandu, Nepal
| | - S Acharya
- Department of Pathology, Kathmandu Medical College, Sinamangal, Kathmandu, Nepal
| | - S Pradhan
- Department of Pathology, Kathmandu Medical College, Sinamangal, Kathmandu, Nepal
| | - S B Shrestha
- Department of Dermatology and Sexually Transmitted Infections, Kathmandu Medical College, Sinamangal, Kathmandu, Nepal
| | - T Itoh
- Department of Diagnostic Pathology, Kobe University Graduate School of Medicine, Kobe, Japan
| |
Collapse
|
31
|
Ogihara K, Itoh T, Mizuno Y, Tamukai K, Madarame H. Disseminated Histiocytic Sarcoma in an African Hedgehog (Atelerix albiventris). J Comp Pathol 2016; 155:361-364. [PMID: 27720131 DOI: 10.1016/j.jcpa.2016.09.001] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2016] [Revised: 09/02/2016] [Accepted: 09/05/2016] [Indexed: 11/17/2022]
Abstract
Disseminated histiocytic sarcoma (HS) was diagnosed on post-mortem examination of a 1.5-year-old African hedgehog (Atelerix albiventris) that was presented in poor physical condition and with diarrhoea. Leucocytosis and a hypoechoic abdominal mass were noted on haematological and ultrasonographical examinations. Gross pathological, histopathological, immunohistochemical and ultrastructural evaluation of the mass supported a diagnosis of disseminated HS. To our knowledge, this report represents the first documentation of disseminated HS in this species.
Collapse
Affiliation(s)
- K Ogihara
- Laboratory of Pathology, School of Life and Environmental Science, Japan
| | - T Itoh
- Laboratory of Small Animal Clinics, Veterinary Teaching Hospital, Azabu University, 1-17-71, Fuchinobe, Chuo, Sagamihara, Kanagawa, Japan
| | - Y Mizuno
- Laboratory of Small Animal Clinics, Veterinary Teaching Hospital, Azabu University, 1-17-71, Fuchinobe, Chuo, Sagamihara, Kanagawa, Japan
| | - K Tamukai
- Den-en-chofu Animal Hospital, 2-1-3 Denenchofu, Ota-ku, Tokyo, Japan
| | - H Madarame
- Laboratory of Small Animal Clinics, Veterinary Teaching Hospital, Azabu University, 1-17-71, Fuchinobe, Chuo, Sagamihara, Kanagawa, Japan.
| |
Collapse
|
32
|
Demetris AJ, Bellamy C, Hübscher SG, O'Leary J, Randhawa PS, Feng S, Neil D, Colvin RB, McCaughan G, Fung JJ, Del Bello A, Reinholt FP, Haga H, Adeyi O, Czaja AJ, Schiano T, Fiel MI, Smith ML, Sebagh M, Tanigawa RY, Yilmaz F, Alexander G, Baiocchi L, Balasubramanian M, Batal I, Bhan AK, Bucuvalas J, Cerski CTS, Charlotte F, de Vera ME, ElMonayeri M, Fontes P, Furth EE, Gouw ASH, Hafezi-Bakhtiari S, Hart J, Honsova E, Ismail W, Itoh T, Jhala NC, Khettry U, Klintmalm GB, Knechtle S, Koshiba T, Kozlowski T, Lassman CR, Lerut J, Levitsky J, Licini L, Liotta R, Mazariegos G, Minervini MI, Misdraji J, Mohanakumar T, Mölne J, Nasser I, Neuberger J, O'Neil M, Pappo O, Petrovic L, Ruiz P, Sağol Ö, Sanchez Fueyo A, Sasatomi E, Shaked A, Shiller M, Shimizu T, Sis B, Sonzogni A, Stevenson HL, Thung SN, Tisone G, Tsamandas AC, Wernerson A, Wu T, Zeevi A, Zen Y. 2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. Am J Transplant 2016; 16:2816-2835. [PMID: 27273869 DOI: 10.1111/ajt.13909] [Citation(s) in RCA: 361] [Impact Index Per Article: 45.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2016] [Revised: 06/01/2016] [Accepted: 05/25/2016] [Indexed: 02/06/2023]
Abstract
The Banff Working Group on Liver Allograft Pathology reviewed and discussed literature evidence regarding antibody-mediated liver allograft rejection at the 11th (Paris, France, June 5-10, 2011), 12th (Comandatuba, Brazil, August 19-23, 2013), and 13th (Vancouver, British Columbia, Canada, October 5-10, 2015) meetings of the Banff Conference on Allograft Pathology. Discussion continued online. The primary goal was to introduce guidelines and consensus criteria for the diagnosis of liver allograft antibody-mediated rejection and provide a comprehensive update of all Banff Schema recommendations. Included are new recommendations for complement component 4d tissue staining and interpretation, staging liver allograft fibrosis, and findings related to immunosuppression minimization. In an effort to create a single reference document, previous unchanged criteria are also included.
Collapse
Affiliation(s)
- A J Demetris
- University of Pittsburgh Medical Center, Pittsburgh, PA
| | - C Bellamy
- The University of Edinburgh, Edinburgh, Scotland
| | | | - J O'Leary
- Baylor University Medical Center, Dallas, TX
| | - P S Randhawa
- University of Pittsburgh Medical Center, Pittsburgh, PA
| | - S Feng
- University of California San Francisco Medical Center, San Francisco, CA
| | - D Neil
- Queen Elizabeth Hospital Birmingham, Birmingham, UK
| | - R B Colvin
- Massachusetts General Hospital, Boston, MA
| | - G McCaughan
- Royal Prince Alfred Hospital, Sydney, Australia
| | | | | | - F P Reinholt
- Oslo University Hospital Rikshospitalet, Oslo, Norway
| | - H Haga
- Kyoto University Hospital, Kyoto, Japan
| | - O Adeyi
- University Health Network and University of Toronto, Toronto, Canada
| | - A J Czaja
- Mayo Clinic College of Medicine, Rochester, MN
| | - T Schiano
- Mount Sinai Medical Center, New York, NY
| | - M I Fiel
- Icahn School of Medicine at Mount Sinai, New York, NY
| | - M L Smith
- Mayo Clinic Health System, Scottsdale, AZ
| | - M Sebagh
- AP-HP Hôpital Paul-Brousse, Paris, France
| | - R Y Tanigawa
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
| | - F Yilmaz
- University of Ege, Faculty of Medicine, Izmir, Turkey
| | | | - L Baiocchi
- Policlinico Universitario Tor Vergata, Rome, Italy
| | | | - I Batal
- Columbia University College of Physicians and Surgeons, New York, NY
| | - A K Bhan
- Massachusetts General Hospital, Boston, MA
| | - J Bucuvalas
- Cincinnati Children's Hospital Medical Center, Cincinnati, OH
| | - C T S Cerski
- Universidade Federal do Rio Grande do Sul, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil
| | | | | | - M ElMonayeri
- Ain Shams University, Wady El-Neel Hospital, Cairo, Egypt
| | - P Fontes
- University of Pittsburgh Medical Center, Pittsburgh, PA
| | - E E Furth
- Hospital of the University of Pennsylvania, Philadelphia, PA
| | - A S H Gouw
- University Medical Center Groningen, Groningen, the Netherlands
| | | | - J Hart
- University of Chicago Hospitals, Chicago, IL
| | - E Honsova
- Institute for Clinical and Experimental Medicine, Prague, Czech Republic
| | - W Ismail
- Beni-Suef University, Beni-Suef, Egypt
| | - T Itoh
- Kobe University Hospital, Kobe, Japan
| | | | - U Khettry
- Lahey Hospital and Medical Center, Burlington, MA
| | | | - S Knechtle
- Duke University Health System, Durham, NC
| | - T Koshiba
- Soma Central Hospital, Soma, Fukushima, Japan
| | - T Kozlowski
- University of North Carolina at Chapel Hill, Chapel Hill, NC
| | - C R Lassman
- David Geffen School of Medicine at UCLA, Los Angeles, CA
| | - J Lerut
- Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - J Levitsky
- Northwestern University Feinberg School of Medicine, Chicago, IL
| | - L Licini
- Pope John XXIII Hospital, Bergamo, Italy
| | - R Liotta
- Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione, University of Pittsburgh Medical Center, Palermo, Italy
| | - G Mazariegos
- Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh, PA
| | - M I Minervini
- University of Pittsburgh Medical Center, Pittsburgh, PA
| | - J Misdraji
- Massachusetts General Hospital, Boston, MA
| | - T Mohanakumar
- St. Joseph's Hospital and Medical Center, Norton Thoracic Institute, Phoenix, AZ
| | - J Mölne
- University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - I Nasser
- Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA
| | - J Neuberger
- Queen Elizabeth Hospital Birmingham, Birmingham, UK
| | - M O'Neil
- University of Kansas Medical Center, Kansas City, KS
| | - O Pappo
- Hadassah Medical Center, Jerusalem, Israel
| | - L Petrovic
- University of Southern California, Los Angeles, CA
| | - P Ruiz
- University of Miami, Miami, FL
| | - Ö Sağol
- School of Medicine, Dokuz Eylul University, Izmir, Turkey
| | | | - E Sasatomi
- University of North Carolina School of Medicine, Chapel Hill, NC
| | - A Shaked
- University of Pennsylvania Health System, Philadelphia, PA
| | - M Shiller
- Baylor University Medical Center, Dallas, TX
| | - T Shimizu
- Toda Chuo General Hospital, Saitama, Japan
| | - B Sis
- University of Alberta Hospital, Edmonton, Canada
| | - A Sonzogni
- Pope John XXIII Hospital, Bergamo, Italy
| | | | - S N Thung
- Icahn School of Medicine at Mount Sinai, New York, NY
| | - G Tisone
- University of Rome-Tor Vergata, Rome, Italy
| | | | - A Wernerson
- Karolinska University Hospital, Stockholm, Sweden
| | - T Wu
- Tulane University School of Medicine, New Orleans, LA
| | - A Zeevi
- University of Pittsburgh, Pittsburgh, PA
| | - Y Zen
- Kobe University Hospital, Kobe, Japan
| |
Collapse
|
33
|
Abstract
The merits and disadvantages of using the silica gel-sintered plate for lipid chromatographic analysis were investigated in detail. The commercially available sintered plate could be used repeatedly, employing the reconditioning procedure which involved chromic-sulfuric acid treatment and subsequent activation. The reconditioned sintered plate has now been used successfully 20 times, for lipid analysis without any deterioration of the excellent resolution power for complex lipid mixtures for all the solvent systems. Since the sintered plate is sturdy, the chromatogplate could be immersed directly in the liquid reaction mixture, so that spots on the chromatogram could be seen and impregnated plates prepared simply. The sintered plate was found to be much more economical than the silica gel-coated plate.
Collapse
Affiliation(s)
- T Itoh
- Division of Chemistry, School of General Studies, Kitasato University, 1-Asamizodai, 228, Sagamihara-shi, Kanagawa-ken, Japan
| | - M Tanaka
- Division of Chemistry, School of General Studies, Kitasato University, 1-Asamizodai, 228, Sagamihara-shi, Kanagawa-ken, Japan
| | - H Kaneko
- Division of Chemistry, School of General Studies, Kitasato University, 1-Asamizodai, 228, Sagamihara-shi, Kanagawa-ken, Japan
| |
Collapse
|
34
|
Ueno K, Sun Q, Mino M, Itoh T, Oshikiri T, Misawa H. Surface plasmon optical antennae in the infrared region with high resonant efficiency and frequency selectivity. Opt Express 2016; 24:17728-17737. [PMID: 27505741 DOI: 10.1364/oe.24.017728] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Infrared light has received attention for sensor applications, including fingerprint spectroscopy, in the bioengineering and security fields. Surface plasmon physics enables the operation of a light harvesting optical antenna. Gold nanochains exhibit localized surface plasmon resonance (LSPR) in the infrared region with high frequency selectivity. However, a feasible design for optical antennae with a higher resonant efficiency and frequency selectivity as a function of structural design and periodicity is still unknown. In the present study, we investigated the relationship between the resonant efficiency and frequency selectivity as a function of the structural design of gold nanochains and explored structural periodicity for obtaining highly frequency-selective optical antennae. An optical antenna design with higher resonant efficiency is proposed on the basis of its efficient interaction with non-polarized light.
Collapse
|
35
|
Abstract
'Pulsatile flow' has been reported to reduce vascular resistance. In this study, the effect of pulsatile flow was assessed quantitatively, using perfusion of canine hindlimb. The perfusion circuit consisted of roller-type pulsatile pump (Cobe Inc., Stockert pump) and bubble oxygenator (Shiley Inc., S-070/s). Each flow curve was quantified with the mean flow rate (F) and pulse power index (PPI). PPI is derived by Fourier transformation of the flow curve and represents the degree of 'pulsation'. Vascular resistance was determined during perfusion with varied flow rate and PPI. The regression formula between vascular resistance (VR) and two parameters was obtained as follows: VR(F,PPI) = 41600x(F-1.37) -0.95+913 - PPIx{(3.99x(F-1.33)-040_0.69} where VR is measured in mmHg. min-1.kg.ml-1; F represents ml.min-1.kg -1 (range from 2.8 to 17.1); and PPI is dimensionless (range from 2.8 to 215.7). Using this formula, vascular resistance at a fixed flow rate and wave form can be predicted. When the flow rate is 6.27 ml.min-1.kg-1 and the PPI is 1466, (measured values under perfusion with own beating heart) the vascular resistance perfused by own beating heart is obtained. The results indicate that the pulsation of own beating heart contributes to a reduction in vascular resistance to 80%. It is also shown that the value of PPI which is necessary to reduce the vascular resistance to 80% is more than 1300 under the normal flow rate range.
Collapse
Affiliation(s)
- A. Sohma
- Department of Surgery Kyoto Pretectural University of Medicine
| | - K. Ohga
- Department of Surgery Kyoto Pretectural University of Medicine
| | - T. Oka
- Department of Surgery Kyoto Pretectural University of Medicine
| | - Y. Oda
- Department of Physiology, Kyoto Prefectural University of Medicine, Kyoto
| | - T. Itoh
- Department of Physiology, Kyoto Prefectural University of Medicine, Kyoto
| | - T. Morimoto
- Department of Physiology, Kyoto Prefectural University of Medicine, Kyoto
| |
Collapse
|
36
|
Yu F, Takahashi T, Moriya J, Kawaura K, Yamakawa J, Kusaka K, Itoh T, Morimoto S, Yamaguchi N, Kanda T. Traditional Chinese Medicine and Kampo: A Review from the Distant past for the Future. J Int Med Res 2016; 34:231-9. [PMID: 16866016 DOI: 10.1177/147323000603400301] [Citation(s) in RCA: 154] [Impact Index Per Article: 19.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Traditional Chinese medicine (TCM) is a complete system of healing that developed in China about 3000 years ago, and includes herbal medicine, acupuncture, moxibustion and massage, etc. In recent decades the use of TCM has become more popular in China and throughout the world. Traditional Japanese medicine has been used for 1500 years and includes Kampo-yaku (herbal medicine), acupuncture and acupressure. Kampo is now widely practised in Japan and is fully integrated into the modern health-care system. Kampo is based on TCM but has been adapted to Japanese culture. In this paper we review the history and characteristics of TCM and traditional Japanese medicine, i.e. the selection of traditional Chinese herbal medicine treatments based on differential diagnosis, and treatment formulations specific for the ‘Sho’ (the patient's symptoms at a given moment) of Japanese Kampo - and look at the prospects for these forms of medicine.
Collapse
Affiliation(s)
- F Yu
- Department of General Medicine, Kanazawa Medical University, Ishikawa, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Oikawa S, Ito S, Odajima C, Horibe Y, Urano S, Suzuki K, Minegishi M, Itoh T, Shibasaki I, Shimizu H. Reproducible delayed appearance of platelet clumps and acanthocytes in blood components collected from a single donor. Transfus Med 2016; 26:69-70. [PMID: 27061618 DOI: 10.1111/tme.12274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2015] [Accepted: 12/18/2015] [Indexed: 11/29/2022]
Affiliation(s)
- S Oikawa
- Japanese Red Cross Tohoku Block Blood Center, Miyagi 981-3206, Japan
| | - S Ito
- Japanese Red Cross Tohoku Block Blood Center, Miyagi 981-3206, Japan
| | - C Odajima
- Japanese Red Cross Tohoku Block Blood Center, Miyagi 981-3206, Japan
| | - Y Horibe
- Japanese Red Cross Tohoku Block Blood Center, Miyagi 981-3206, Japan
| | - S Urano
- Japanese Red Cross Tohoku Block Blood Center, Miyagi 981-3206, Japan
| | - K Suzuki
- Japanese Red Cross Tohoku Block Blood Center, Miyagi 981-3206, Japan
| | - M Minegishi
- Japanese Red Cross Tohoku Block Blood Center, Miyagi 981-3206, Japan
| | - T Itoh
- Japanese Red Cross Tohoku Block Blood Center, Miyagi 981-3206, Japan
| | - I Shibasaki
- Aomori Red Cross Blood Center, Aomori 030-0966, Japan
| | - H Shimizu
- Japanese Red Cross Tohoku Block Blood Center, Miyagi 981-3206, Japan
| |
Collapse
|
38
|
Hida T, Oya Y, Tanaka K, Yoshida T, Shimizu J, Horio Y, Yatabe Y, Itoh T, Shin W. 12P Volatolomic signatures of anaplastic lymphoma kinase gene rearrangement in adenocarcinoma. J Thorac Oncol 2016. [DOI: 10.1016/s1556-0864(16)30126-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
39
|
Kajita T, Itoh T. Electrochemical performance of highly amorphous GeOx powders synthesized in different alcohols for use in Na- and Li-ion batteries. RSC Adv 2016. [DOI: 10.1039/c6ra20794d] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
The large particle size of amorphous powders deteriorated the cycle performance of a Na-ion cell more than that of a Li-ion cell, due to large decomposition of the electrolyte.
Collapse
Affiliation(s)
- T. Kajita
- Frontier Research Institute for Interdisciplinary Sciences (FRIS)
- Tohoku University
- Sendai-shi
- Japan
| | - T. Itoh
- Frontier Research Institute for Interdisciplinary Sciences (FRIS)
- Tohoku University
- Sendai-shi
- Japan
| |
Collapse
|
40
|
Yamamoto YS, Fujime Y, Takahashi N, Nakanishi S, Itoh T. Formation mechanism of plasmonic silver nanohexagonal particles made by galvanic displacement reaction. RSC Adv 2016. [DOI: 10.1039/c6ra00685j] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Multi-element XPS depth profile analysis made clear that Ag nanoscale hexagonal columns formed by newly-discovered galvanic displacement reaction are covered with Cu compounds which prevent Ag columns from fusion, resulting in stable hotspots.
Collapse
Affiliation(s)
- Y. S. Yamamoto
- Department of Advanced Materials Sciences
- Faculty of Engineering
- Kagawa University
- Takamatsu
- Japan
| | - Y. Fujime
- Department of Physics
- Faculty of Education
- Kagawa University
- Takamatsu
- Japan
| | - N. Takahashi
- Department of Physics
- Faculty of Education
- Kagawa University
- Takamatsu
- Japan
| | - S. Nakanishi
- Department of Advanced Materials Sciences
- Faculty of Engineering
- Kagawa University
- Takamatsu
- Japan
| | - T. Itoh
- Nano-Bioanalysis Research Group
- Health Research Institute
- National Institute of Advanced Industrial Science and Technology (AIST)
- Takamatsu
- Japan
| |
Collapse
|
41
|
Hikishima K, Ando K, Komaki Y, Kawai K, Yano R, Inoue T, Itoh T, Yamada M, Momoshima S, Okano HJ, Okano H. Voxel-based morphometry of the marmoset brain: In vivo detection of volume loss in the substantia nigra of the MPTP-treated Parkinson's disease model. Neuroscience 2015; 300:585-92. [PMID: 26012491 DOI: 10.1016/j.neuroscience.2015.05.041] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2015] [Revised: 05/14/2015] [Accepted: 05/16/2015] [Indexed: 11/30/2022]
Abstract
Movement dysfunction in Parkinson's disease (PD) is caused by the degeneration of dopaminergic (DA) neurons in the substantia nigra (SN). Here, we established a method for voxel-based morphometry (VBM) and automatic tissue segmentation of the marmoset monkey brain using a 7-T animal scanner and applied the method to assess DA degeneration in a PD model, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated animals, with tyrosine-hydroxylase staining. The most significant decreases of local tissue volume were detected in the bilateral SN of MPTP-treated marmoset brains (-53.0% in right and -46.5% in left) and corresponded with the location of DA neurodegeneration found in histology (-65.4% in right). In addition to the SN, the decreases were also confirmed in the locus coeruleus, and lateral hypothalamus. VBM using 7-T MRI was effective in detecting volume loss in the SN of the PD-model marmoset. This study provides a potential basis for the application of VBM with ultra-high field MRI in the clinical diagnosis of PD. The developed method may also offer value in automatic whole-brain evaluation of structural changes for the marmoset monkey.
Collapse
Affiliation(s)
- K Hikishima
- Department of Physiology, Keio University School of Medicine, Tokyo, Japan; Central Institute for Experimental Animals, Kawasaki, Japan
| | - K Ando
- Central Institute for Experimental Animals, Kawasaki, Japan
| | - Y Komaki
- Department of Physiology, Keio University School of Medicine, Tokyo, Japan; Central Institute for Experimental Animals, Kawasaki, Japan
| | - K Kawai
- Central Institute for Experimental Animals, Kawasaki, Japan
| | - R Yano
- Department of Physiology, Keio University School of Medicine, Tokyo, Japan
| | - T Inoue
- Central Institute for Experimental Animals, Kawasaki, Japan
| | - T Itoh
- Central Institute for Experimental Animals, Kawasaki, Japan
| | - M Yamada
- Faculty of Radiological Technology, Fujita Health University School of Health Sciences, Toyoake, Japan
| | - S Momoshima
- Department of Diagnostic Radiology, Keio University School of Medicine, Tokyo, Japan
| | - H J Okano
- Division of Regenerative Medicine, Jikei University School of Medicine, Tokyo, Japan
| | - H Okano
- Department of Physiology, Keio University School of Medicine, Tokyo, Japan; Laboratory for Marmoset Neural Architecture, Brain Science Institute RIKEN, Wako, Japan.
| |
Collapse
|
42
|
Abstract
In a total of 283 biopsies, 100 (35%) were found to be IgA nephropathy. The incidence reached 40% among primary glomerulonephropathies. On the basis of histopathologic changes in glomeruli, these biopsies were classified into 3 groups. The criteria employed correlated well with clinical, laboratory and immunofluorescent findings. Immune complex pathogenesis was discussed in relation to our findings.
Collapse
|
43
|
Yano T, Miki T, Itoh T, Ohnishi H, Asari M, Chihiro S, Yamamoto A, Aotsuka K, Kawakami N, Ichikawa J, Hirota Y, Miura T. IQ is an independent predictor of glycated haemoglobin level in young and middle-aged adults with intellectual disability. Diabet Med 2015; 32:129-32. [PMID: 24984892 DOI: 10.1111/dme.12547] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/04/2014] [Revised: 04/22/2014] [Accepted: 06/27/2014] [Indexed: 11/28/2022]
Abstract
AIMS Here we examined whether intellectual disability is independently associated with hyperglycaemia. METHODS We recruited 233 consecutive young and middle-aged adults with intellectual disability. After exclusion of subjects on medication for metabolic diseases or with severe intellectual disability (IQ < 35), 121 subjects were divided by IQ into a group with moderate intellectual disability (35 ≤ IQ ≤ 50), a mild intellectual disability group (51 ≤ IQ ≤ 70) and a borderline group (IQ > 70). RESULTS HbA1c level was higher in subjects with moderate intellectual disability (42 ± 9 mmol/mol; 6.0 ± 0.8%) than those in the borderline group (36 ± 4 mmol/mol; 5.5 ± 0.3%) and mild intellectual disability group (37 ± 5 mmol/mol; 5.5 ± 0.5%) groups. HbA1c level was correlated with age, BMI, blood pressure, serum triglycerides and IQ in simple linear regression analysis. Multiple regression analysis indicated that IQ, age, BMI and diastolic blood pressure were independent explanatory factors of HbA1c level. CONCLUSIONS An unfavourable effect of intellectual disability on lifestyle and untoward effect of hyperglycaemia on cognitive function may underlie the association of low IQ with hyperglycaemia.
Collapse
Affiliation(s)
- T Yano
- The Counseling Center for the Handicapped in Hokkaido, Sapporo, Japan; Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Futagami S, Itoh T, Sakamoto C. Systematic review with meta-analysis: post-infectious functional dyspepsia. Aliment Pharmacol Ther 2015; 41:177-88. [PMID: 25348873 DOI: 10.1111/apt.13006] [Citation(s) in RCA: 94] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/30/2013] [Revised: 10/23/2013] [Accepted: 10/09/2014] [Indexed: 12/13/2022]
Abstract
BACKGROUND The prevalence of functional dyspepsia (FD) following infectious gastroenteritis has not been systematically reviewed. AIM To conduct a systematic review and calculate the summary odds ratio (OR) for the development of FD following infectious gastroenteritis, as compared to a control population. METHODS Published studies in PubMed, EmBASE, and Cochrane Database and abstracts from standard sources were screened for eligible studies. Data from studies meeting inclusion criteria were pooled for meta-analysis. RESULTS Nineteen studies were eligible for inclusion. The mean prevalence of FD following acute gastroenteritis (AGE) was 9.55% (FD, n = 909; AGE, n = 9517) in adult populations. The summary OR for the development of post-infectious FD was 2.54 (95% CI = 1.76-3.65) at more than 6 months after AGE, as compared to the prevalence in controls within the same population. This is compared with the summary OR (3.51; 95% CI = 2.05-6.00) for the development of post-infectious irritable bowel syndrome (IBS) in the same population at more than 6 months after AGE. There was significant statistical heterogeneity with an I(2) of 72.8% for the summary OR of post-infectious FD. Several pathogens, including Salmonella spp., Escherichia coli O157, Campylobacter jejuni, Giardia lamblia and Norovirus have been shown to be associated with post-infectious FD symptoms. CONCLUSIONS Infectious gastroenteritis is associated with an increased risk for subsequent dyspepsia as well as for irritable bowel syndrome. Post-infectious FD and post-infectious irritable bowel syndrome may represent different aspects of the same pathophysiology. Further studies will be needed to determine this.
Collapse
Affiliation(s)
- S Futagami
- Department of Medicine, Division of Gastroenterology, Nippon Medical School, Tokyo, Japan
| | | | | |
Collapse
|
45
|
Shimoda M, Itoh T, Sugimoto K, Takita M, Chujo D, Iwahashi S, SoRelle JA, Naziruddin B, Levy MF, Grayburn PA, Matsumoto S. An effective method to release human islets from surrounding acinar cells with agitation in high osmolality solution. Transplant Proc 2014; 43:3161-6. [PMID: 22099746 DOI: 10.1016/j.transproceed.2011.09.098] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
Abstract
INTRODUCTION Islet purification is mainly performed by the density gradient method. However, purification of the embedded islets that are surrounded by exocrine tissue should be difficult, because their density is similar to exocrine tissue. In this study, we performed chart review to assess the relationship between the ratio of embedded islets and efficacy of purification. Then, we tested several conditions of a new method to free the islets from surrounded exocrine tissues using high osmolality solution with gentle agitation. MATERIALS AND METHODS First, we performed chart review of our human islet isolation. Second, embedded islet-enriched human islet fractions (embedded islets >50%) were suspended in University of Wisconsin (UW) solution (UW group, 320 mOsm/kg/H(2)0) or osmolality-adjusted UW solution (400, 500, and 600 mOsm/kg/H(2)0; 400 group, 500 group, and 600 group, respectively). Each tube was gently shaken at 4°C. The tissue samples were taken before shaking and after 15, 30, and 60 minutes. Islet yield, percentage of embedded islets, and viabilities were assessed. RESULTS The chart review revealed that high ratio of embedded islets deteriorated the efficacy of islet purification. The islet yield in all groups except for the 600 group did not change at 15 minutes, but it decreased in all groups at 60 minutes. The average percentage of embedded islets before shaking was 62.6%. Although percentage of embedded islets were decreasing in all groups, it was < 20% at 15 minutes in the 500 and 600 groups whereas it was >44% in the UW group, which indicated that higher osmolality would have a greater effect. Viability was >95% in all groups at 30 minutes. CONCLUSIONS The embedded islets deteriorated the efficacy of islet purification. Gentle agitation of embedded islets in high osmolality (500 mOsm/kg/H(2)O, 15 minutes) could release islets from surrounded exocrine tissue.
Collapse
Affiliation(s)
- M Shimoda
- Baylor Research Institute, Dallas, Texas, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Matsumoto S, Takita M, Shimoda M, Itoh T, Iwahashi S, Chujo D, SoRelle JA, Tamura Y, Rahman A, Purcell K, Onaca N, Naziruddin B, Levy MF. Usefulness of the secretory unit of islet transplant objects (SUITO) index for evaluation of clinical autologous islet transplantation. Transplant Proc 2014; 43:3246-9. [PMID: 22099768 DOI: 10.1016/j.transproceed.2011.10.036] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
BACKGROUND Assessing the engrafted islet mass is important in evaluating the efficacy of islet transplantation. We previously demonstrated that the average secretory unit of islet transplant objects (SUITO) index within 1 month of allogeneic islet transplantation was an excellent predictor of insulin independence. However, the usefulness of the SUITO index for evaluating autologous islet transplantation has not been explored. The purpose of the present study was to assess the relationship between the SUITO index and clinical outcomes after total pancreatectomy followed by autologous islet transplantation. METHODS We performed 27 total pancreatectomies followed by autologous islet transplantation from October 2006 to January 2011. Cases were divided into an insulin-independent group (IIG; n = 12) and an insulin-dependent group (lDG; n = 15). The SUITO index was calculated by the formula [fasting C-peptide (ng/mL)/fasting glucose (mg/dL) -63] × 1,500. The average SUITO index within the first month of transplantation except for days 0, 1, and 2, maximum SUITO index, and most recent SUITO index were calculated in each case, and values were compared between the IIG and the IDG. RESULTS The average SUITO index within 1 month was significantly higher in the IIG than in the IDG (24.6 ± 3.4 vs 14.9 ± 2.0, respectively; P < .02). The maximum SUITO indices were 45.7 ± 7.7 in the IIG and 30.1 ± 8.1 in the IDG (not significant), and the recent SUITO indices were 36.9 ± 6.7 in the IIG and 22.8 ± 6.1 in the IDG (not significant). CONCLUSIONS The average SUITO index within 1 month was an excellent predictor of insulin independence after total pancreatectomy followed by autologous islet transplantation.
Collapse
Affiliation(s)
- S Matsumoto
- Baylor Research Institute, Dallas, Texas, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Mori T, Itoh T, Yoshizawa K, Saeki T, Masukawa D, Shibasaki M, Suzuki T. P-44 * INVOLVEMENT OF MU- AND DELTA-OPIOID RECEPTOR FUNCTION IN THE REWARDING EFFECT OF PENTAZOCINE. Alcohol Alcohol 2014. [DOI: 10.1093/alcalc/agu054.44] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
48
|
Anazawa T, Saito T, Goto M, Kenmochi T, Uemoto S, Itoh T, Yasunami Y, Kenjo A, Kimura T, Ise K, Tsuchiya T, Gotoh M. Long-Term Outcomes of Clinical Transplantation of Pancreatic Islets With Uncontrolled Donors After Cardiac Death: A Multicenter Experience in Japan. Transplant Proc 2014; 46:1980-4. [DOI: 10.1016/j.transproceed.2014.06.006] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
49
|
Hiratsuka I, Suzuki A, Kondo-Ando M, Hirai H, Maeda Y, Sekiguchi-Ueda S, Shibata M, Takayanagi T, Makino M, Fukami N, Itoh T, Sasaki H, Kusaka M, Kenmochi T, Hoshinaga K, Itoh M. Utility of Glucagon Stimulation Test in Type 1 Diabetes After Pancreas Transplantation. Transplant Proc 2014; 46:967-9. [DOI: 10.1016/j.transproceed.2013.11.027] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2013] [Accepted: 11/06/2013] [Indexed: 10/25/2022]
|
50
|
Takechi M, Suzuki S, Nishimura D, Fukuda M, Ohtsubo T, Nagashima M, Suzuki T, Yamaguchi T, Ozawa A, Moriguchi T, Ohishi H, Sumikama T, Geissel H, Ishihara M, Aoi N, Chen RJ, Fang DQ, Fukuda N, Fukuoka S, Furuki H, Inabe N, Ishibashi Y, Itoh T, Izumikawa T, Kameda D, Kubo T, Lee CS, Lantz M, Ma YG, Matsuta K, Mihara M, Momota S, Nagae D, Nishikiori R, Niwa T, Ohnishi T, Okumura K, Ogura T, Sakurai H, Sato K, Shimbara Y, Suzuki H, Takeda H, Takeuchi S, Tanaka K, Uenishi H, Winkler M, Yanagisawa Y, Watanabe S, Minomo K, Tagami S, Shimada M, Kimura M, Matsumoto T, Shimizu YR, Yahiro M. Search for halo nucleus in Mg isotopes through the measurements of reaction cross sections towards the vicinity of neutron drip line. EPJ Web of Conferences 2014. [DOI: 10.1051/epjconf/20146602101] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|